AC Immune to Present at the Jefferies 2024 London Healthcare Conference

ACIU 11.13.2024

Full Press ReleaseSEC FilingsOur ACIU Tweets

About Gravity Analytica

Recent News

  • 12.10.2024 - AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome
  • 11.20.2024 - Jefferies 2024 London Healthcare Conference
  • 11.14.2024 - AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease

Recent Filings

  • 12.18.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
  • 12.13.2024 - SC 13G/A Statement of Beneficial Ownership by Certain Investors
  • 12.10.2024 - EX-99.1 EX-99.1
PDF Version120.1 KB

AC Immuneto Present at the Jefferies 2024London Healthcare Conference

Lausanne,Switzerland,November 13, 2024–AC Immune SA(NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company Management will participate in a fireside chat and one-on-one investor meetings during the Jefferies 2024London Healthcare Conference, taking place in-person inLondononNovember 19-21, 2024.

The fireside chat will take place onNovember 20, 2024, at6:00 AM (ET)/11:00 AM (GMT). A webcast of the fireside chat will be available on theEvents Pageof AC Immune’s website. A replay will be archived in the same location.

Please contact your Jefferies representative to request a meeting with AC Immune’s management team at the conference.

AboutAC Immune SAAC Immune SAis a clinical-stage biopharmaceutical company and a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen®and Morphomer®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features sixteen therapeutic and diagnostic programs, five of which are currently in Phase 2 clinical trials and one of which is in Phase 3.AC Immunehas a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding in potential milestone payments plus royalties.

SupraAntigen®is a registered trademark ofAC Immune SAin the following territories: AU, EU, CH, GB, JP, RU, SG andUSA. Morphomer®is a registered trademark ofAC Immune SAin CN, CH, GB, JP, KR, NO and RU.

The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release.

For further information, please contact:

Head of Investor Relations & Corporate CommunicationsGary Waanders, Ph.D., MBAAC ImmunePhone: +41 21 345 91 91Email:gary.waanders@acimmune.comU.S. InvestorsChristina TartagliaPrecision AQPhone: +1 212 362 1200Email:christina.tartaglia@precisionaq.com
International MediaChris MaggosCohesion BureauPhone: +41 79 367 6254Email:chris.maggos@cohesionbureau.com

Forward looking statementsThis press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with theSecurities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.

Attachment

  • 20241113_ACIU_Jefferies curtain raiser

Primary Logo

Source: AC Immune SA

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com